SABSW — SAB Biotherapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1833214 ·
Last close
$0.02
Market Cap
—
52W High
$0.04
52W Low
$0.01
ADV30
292,648
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -19,997,736 | -18,868,885 | 248,470,498 | 20,519,724 | 21,222,197 |
| Dec 2025 | 0 | — | -15,770,231 | -16,860,743 | 172,809,969 | 10,502,680 | 21,315,594 |
| Sep 2025 | 0 | — | -12,678,969 | 45,445,469 | 183,448,368 | 29,424,708 | 18,374,019 |
| Jun 2025 | 0 | — | -9,732,061 | -10,114,270 | 30,129,488 | 3,692,217 | 18,113,273 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-51,249,024
Investing CF
$-192,024,909
Financing CF
$258,394,558
CapEx
$-1,138,934
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-129,764,052
Inventory
—
Receivables
$1,555,061
ST Investments
$86,871,857
EBIT TTM
$-164,585
Pretax Income TTM
$-398,429
Interest Exp TTM
$233,844
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -48,953,363 | 13,273,683 | 172,809,969 | 21,315,594 | — | -44,775,111 |
| Dec 2024 | 0 | -42,910,520 | -34,105,309 | 44,195,469 | 18,225,893 | — | -34,292,009 |
| Dec 2023 | 0 | -38,075,320 | -42,193,786 | 83,941,253 | 26,641,812 | — | -25,119,405 |
| Dec 2022 | 0 | -28,917,617 | -18,740,804 | 50,904,927 | 19,846,785 | — | -23,459,511 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AMGN | AMGEN INC | $207.87B | $385.16 | — |
| GILD | GILEAD SCIENCES, INC. | $161.66B | $130.21 | — |
| ARGX | ARGENX SE | $53.42B | $853.82 | — |
| RVMD | Revolution Medicines, Inc. | $39.87B | $187.53 | — |
| BIIB | BIOGEN INC. | $29.99B | $202.95 | — |
News headlines (Yahoo Finance, 1h cache)
SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET
2026-07-30 12:30 · Yahoo
SAB Biotherapeutics (SABS) and Breakthrough T1D Award Research Grant For SAB-142 Assessment
2026-07-15 15:43 · Yahoo
Why Is H.C. Wainwright Bullish On SAB Biotherapeutics (SABS) With $10 Price Target?
2026-07-05 22:08 · Yahoo
Barclays Assigns Overweight Rating to SAB Biotherapeutics Inc. (SABS)
2026-06-30 16:34 · Yahoo
SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting
2026-05-29 12:00 · Yahoo
Emergent BioSolutions Inc. (EBS) Gains Attention as ACAM2000 Receives Broader Public Health Authorization
2026-05-20 20:43 · Yahoo
We Think SAB Biotherapeutics (NASDAQ:SABS) Needs To Drive Business Growth Carefully
2026-05-15 11:32 · Yahoo
SAB Biotherapeutics Inc (SABS) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Rising ...
2026-05-12 23:03 · Yahoo
SAB Biotherapeutics Q1 Earnings Call Highlights
2026-05-12 17:14 · Yahoo
SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights
2026-05-12 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.